|
1
|
Bellentani S, Scaglioni F, Marino M and
Bedogni G: Epidemiology of non-alcoholic fatty liver disease. Dig
Dis. 28:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lazo M and Clark JM: The epidemiology of
nonalcoholic fatty liver disease: A global perspective. Semin Liver
Dis. 28:339–350. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH
and Li YM: Prevalence of nonalcoholic fatty liver disease and
economy. Dig Dis Sci. 60:3194–3202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vanni E, Bugianesi E, Kotronen A, de
Minicis S, Yki-Järvinen H and Svegliati-Baroni G: From the
metabolic syndrome to NAFLD or vice versa? Dig Liver Dis.
42:320–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li L, Liu DW, Yan HY, Wang ZY, Zhao SH and
Wang B: Obesity is an independent risk factor for non-alcoholic
fatty liver disease: Evidence from a meta-analysis of 21 cohort
studies. Obes Rev. 17:510–519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao ZH, Liu XL and Fan JG: Research on
the natural history of non-alcoholic fatty liver disease should be
taken seriously. Zhonghua Gan Zang Bing Za Zhi. 25:81–84. 2017.(In
Chinese). PubMed/NCBI
|
|
7
|
Bhala N, Angulo P, van der Poorten D, Lee
E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping
JH, Bugianesi E, et al: The natural history of nonalcoholic fatty
liver disease with advanced fibrosis or cirrhosis: An international
collaborative study. Hepatology. 54:1208–1216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duvnjak M, Tomasic V, Gomercic M, Smircic
Duvnjak L, Barsic N and Lerotic I: Therapy of nonalcoholic fatty
liver disease: Current status. J Physiol Pharmacol. 60(Suppl 7):
57–66. 2009.PubMed/NCBI
|
|
9
|
Narayanaswami V and Dwoskin LP: Obesity:
Current and potential pharmacotherapeutics and targets. Pharmacol
Ther. 170:116–147. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kushner RF: Medical management of obesity.
Semin Gastrointest Dis. 13:123–132. 2002.PubMed/NCBI
|
|
11
|
Ali Khan R, Kapur P, Jain A, Farah F and
Bhandari U: Effect of orlistat on periostin, adiponectin,
inflammatory markers and ultrasound grades of fatty liver in obese
NAFLD patients. Ther Clin Risk Manag. 13:139–149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Z, Liang B, Wang Y and Fan X: The
analysis of the efficacy and risk factors in obesity with
non-alcoholic fatty liver disease subjects treated with orlistat.
Chin J Clin Hepatol. 22:123–124. 2006.(In Chinese).
|
|
13
|
Harrison SA, Fincke C, Helinski D,
Torgerson S and Hayashi P: A pilot study of orlistat treatment in
obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol
Ther. 20:623–628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fernández S and Córdoba M: Progesterone
causes metabolic changes involving aminotransferases and creatine
kinase in cryopreserved bovine spermatozoa. Anim Reprod Sci.
164:90–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruinsma BG, Wu W, Ozer S, Farmer A,
Markmann JF, Yeh H and Uygun K: Warm ischemic injury is reflected
in the release of injury markers during cold preservation of the
human liver. PLoS One. 10:e01234212015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Filippatos TD, Derdemezis CS, Gazi IF,
Nakou ES, Mikhailidis DP and Elisaf MS: Orlistat-associated adverse
effects and drug interactions: A critical review. Drug Saf.
31:53–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zelber-Sagi S, Kessler A, Brazowsky E,
Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z and Oren
R: A double-blind randomized placebo-controlled trial of orlistat
for the treatment of nonalcoholic fatty liver disease. Clin
Gastroenterol Hepatol. 4:639–644. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. Int J Surg. 8:336–341.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Furlan AD, Pennick V, Bombardier C and van
Tulder M; Editorial Board, Cochrane Back Review Group: 2009 updated
method guidelines for systematic reviews in the Cochrane Back
Review Group. Spine. 34:1929–1941. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Xue J, Chen P, Chen L, Yan S and Liu
L: Prevalence of nonalcoholic fatty liver disease in mainland of
China: A meta-analysis of published studies. J Gastroenterol
Hepatol. 29:42–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan Z, Qiu D, Xie W, Hu H, Chen Y, Sun Z,
Liu S and Zeng M: Clinical study of obesity associated
non-alcoholic fatty liver disease. Chin Hepatol. 9:155–158.
2004.(In Chinese).
|
|
23
|
Harrison SA, Fecht W, Brunt EM and
Neuschwander-Tetri BA: Orlistat for overweight subjects with
nonalcoholic steatohepatitis: A randomized, prospective trial.
Hepatology. 49:80–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hussein O, Grosovski M, Schlesinger S,
Szvalb S and Assy N: Orlistat reverse fatty infiltration and
improves hepatic fibrosis in obese patients with nonalcoholic
steatohepatitis (NASH). Dig Dis Sci. 52:2512–2519. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Angulo P, Hui JM, Marchesini G, Bugianesi
E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et
al: The NAFLD fibrosis score: A noninvasive system that identifies
liver fibrosis in patients with NAFLD. Hepatology. 45:846–854.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahboub P, Ottens P, Seelen M, 't Hart N,
van Goor H, Ploeg R, Martins PN and Leuvenink H: Gradual rewarming
with gradual increase in pressure during machine perfusion after
cold static preservation reduces kidney ischemia reperfusion
injury. PLoS One. 11:e01520062016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tilg H and Moschen A: Weight loss:
Cornerstone in the treatment of non-alcoholic fatty liver disease.
Minerva Gastroenterol Dietol. 56:159–167. 2010.PubMed/NCBI
|
|
28
|
Gabriel FS, Samson CE, Abejuela ZR,
Sicat-Gabriel PR, Sumpio JP, Zacarias MB and Mercado-Asis LB:
Postprandial effect of orlistat on the peaking of lipid level after
sequential high fat meals. Int J Endocrinol Metab. 10:458–463.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakou ES, Filippatos TD, Agouridis AP,
Kostara C, Bairaktari ET and Elisaf MS: The effects of ezetimibe
and/or orlistat on triglyceride-rich lipoprotein metabolism in
obese hypercholesterolemic patients. Lipids. 45:445–450. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kujawska-Łuczak M, Musialik K, Szulińska
M, Swora-Cwynar E, Kargulewicz A, Grzymisławska M, Pupek-Musialik D
and Bogdański P: The effect of orlistat versus metformin on body
composition and insulin resistance in obese premenopausal women:
3-month randomized prospective open-label study. Arch Med Sci.
13:725–731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scheen AJ and van Gaal LF: Combating the
dual burden: Therapeutic targeting of common pathways in obesity
and type 2 diabetes. Lancet Diabetes Endocrinol. 2:911–922. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smith-Marsh D: Pharmacological strategies
for preventing type 2 diabetes in patients with impaired glucose
tolerance. Drugs Today (Barc). 49:499–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chalasani N, Younossi Z, Lavine JE, Diehl
AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ; American
Gastroenterological Association; American Association for the Study
of Liver Diseases; American College of Gastroenterologyh: The
diagnosis and management of non-alcoholic fatty liver disease:
Practice guideline by the American Gastroenterological Association,
American Association for the Study of Liver Diseases, and American
College of Gastroenterology. Gastroenterology. 142:1592–1609. 2012.
View Article : Google Scholar : PubMed/NCBI
|
